In the current study, we induced resistance to gefitinib in an NSCLC patient-derived xenograft (PDX) model and used this model to investigate the role of S6K1 in acquired EGFR-TKI resistance. The gene discussed is RPS6KB1; the disease is non-small cell lung carcinoma.